Allergan Aesthetics Initiates Charitable Program for Skin Cancer Awareness
As part of its commitment to skin health, Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced a significant charitable initiative for Skin Cancer Awareness Month. This initiative takes place throughout May 2026 and aims to raise awareness about skin cancer prevention while contributing directly to The Skin Cancer Foundation.
The Allē Referral Program
Through its loyalty rewards program, Allē, Allergan Aesthetics will donate $10 to The Skin Cancer Foundation for each new member who joins via referrals during May, up to a maximum contribution of $100,000. Existing members who refer new participants will benefit too, receiving a discount on their next treatment. New members will also enjoy a $50 discount on their first Allergan Aesthetics treatment. This dual benefit not only elevates community involvement but also incentivizes participation, fostering a growing concern for skin health awareness.
Nicole Mowad-Nassar, Senior Vice President at AbbVie as well as President of Global Allergan Aesthetics, emphasized the company's mission: “As a leader in aesthetics, our commitment extends beyond treatment to education, prevention, and long-term skin health. Through Allē and our Members, we're able to activate the community in a meaningful way by encouraging them to share the program while supporting broader awareness around skin cancer and the importance of protecting skin health every day.”
The Urgency of Skin Cancer Awareness
Skin cancer stands as the most prevalent cancer in the United States, with millions of new cases reported every year. The Skin Cancer Foundation warns that one in five Americans will be diagnosed with skin cancer by the age of 70, and having five or more sunburns can double the risk of melanoma. Therefore, fostering knowledge and providing early detection methods are crucial.
Dr. Mona Gohara, a board-certified dermatologist, points out that preventive measures begin with daily habits: “Prevention starts with wearing broad-spectrum sunscreen with an SPF of 30 or above, seeking shade during peak UV hours, and avoiding tanning beds. Regular self-examinations and annual dermatologist visits are essential for early detection.”
Collaboration for a Common Goal
Allergan Aesthetics is joining forces with The Skin Cancer Foundation to amplify their shared mission to protect skin health. Deborah S. Sarnoff, MD, President of The Skin Cancer Foundation, stated, “Education is one of the most powerful tools we have in preventing skin cancer. By partnering with Allergan Aesthetics, we have an opportunity to reach more people with life-saving information about sun safety and early detection, which is at the core of our mission.”
How to Join the Initiative
People interested in taking part in the program can visit
www.alle.com to become a member. Referrals need to be made through the Allē app by selecting the 'Refer a Friend' feature, which allows users to share a unique referral link. The program stipulates terms and conditions, including a cap on referral offers, requiring approval from the referred friend for the referral rewards to be valid.
About Allē and The Skin Cancer Foundation
Allē is recognized as the leading aesthetics loyalty program from Allergan Aesthetics, boasting a membership of over eight million. This platform enables members to earn points across an extensive range of products and treatments while offering numerous savings opportunities. Conversely, the Skin Cancer Foundation, a 501(c)(3) nonprofit organization, is dedicated to promoting proactive sun protection and facilitating early detection of skin cancer through public education and outreach.
In conclusion, Allergan Aesthetics is not just focusing on aesthetic enhancements but is dedicated to an essential cause that impacts millions—skin cancer awareness and prevention. Through its partnership with The Skin Cancer Foundation and the Allē program, the company aims to bolster community engagement while emphasizing the importance of skin health in everyday life.